Cencora Inc (COR) Stock Up 3.6% and Still Undervalued -- GF Score: 79/100
On May 22, 2026, Cencora Inc (COR) shares rose by 3.6% to a current price of $274.91. The stock has experienced a 52-week range between $244.82 and $377.54, ref
On May 22, 2026, Cencora Inc (COR) shares rose by 3.6% to a current price of $274.91. The stock has experienced a 52-week range between $244.82 and $377.54, ref
U.S. drug distributor Cencora on Thursday raised the lower end of its fiscal 2026 earnings forecast citing recent share repurchases, and also approved a new $2 billion stock buyback plan.
CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) today updated its fiscal year 2026 financial guidance as a result of recent opportunistic share repurchases. Cencora now expects adjusted diluted earnings per share to be in the range of $17.70 to $17.90, up from the previous range of $17.65 to $17.90. The opportunistic share repurchases completed in May align with the Company's previously disclosed expectation that it will repurchase $1.0 billion in shares of common stock by the end.
NEW YORK, May 21, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Cencora, Inc. ("Cencora" or the "Company") (NYSE: COR). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
NEW YORK, May 19, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Cencora, Inc. (“Cencora” or the “Company”) (NYSE: COR). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
LOS ANGELES, May 18, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cencora, Inc. (“Cencora” or “the Company”) (NYSE: COR) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
NEW YORK--(BUSINESS WIRE)--Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Cencora, Inc. (NYSE: COR) resulting from allegations that Cencora may have issued materially misleading business information to the investing public. So What: If you purchased Cencora securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. The Rose.
NEW YORK, May 14, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Cencora, Inc. ("Cencora" or the "Company") (NYSE: COR). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Cencora, Inc. (COR) Presents at BofA Securities 2026 China Conference Transcript
Cencora, Inc. (COR) Presents at Bank of America Global Healthcare Conference 2026 Transcript
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay Wolke & Rotter LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Cencora, Inc. (“Cencora” or the “Company”) (NYSE: COR) investors concerning the Company's possible violations of the federal securities laws.IF YOU ARE AN INVESTOR WHO LOST MONEY ON CENCORA, INC. (COR), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS.What Happened?On May 6, 2026, Cenco.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of Cencora, Inc. (“Cencora” or the “Company”) (NYSE: COR) investors concerning the Company's possible violations of federal securities laws.IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN CENCORA, INC. (COR), CONTACT THE LAW OFFICES OF HOWARD G. SMITH ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS.Contact the Law Offices of Howard G. Smith to discuss your legal rights by email at howardsmith.
Cencora NYSE: COR reported higher fiscal second-quarter adjusted earnings and operating income, while management raised its full-year adjusted EPS outlook and said it would resume opportunistic share repurchases. The pharmaceutical distribution and healthcare services company also lowered its full-year revenue growth expectations, citing faster-than-anticipated brand conversions at a large mail-order pharmacy customer and slower expected growth in GLP-1 products.
LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of Cencora, Inc. (“Cencora” or the “Company”) (NYSE: COR) on behalf of investors concerning the Company's possible violations of federal securities laws. IF YOU ARE AN INVESTOR WHO LOST MONEY ON CENCORA, INC. (COR), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING A CLAIM TO RECOVER YOUR LOSS. What Is The Investigation About? On May 6, 2026, Cencora released its second quarter 2026 financial results, inclu.
Cencora reported Q2 results with 3.8% revenue growth and a 129% EPS increase, but shares fell sharply, apparently due to a revenue miss. Despite a forward P/E of ~14 and manageable debt, COR faces thin margins, client concentration risks, and headwinds from biosimilars and drug price reductions. Management remains confident, targeting $3B in free cash flow and $1B in share repurchases for 2026, with ongoing M&A to expand specialty services.
Cencora, Inc. (COR) Q2 2026 Earnings Call Transcript
Shares of Cencora Inc. (NASDAQ:COR) are trading lower on Wednesday as the company reported its fiscal 2026 second-quarter results and lowered its annual guidance.
Cencora shares sink after Q2 earnings and revenues miss estimates, even as the company raises its fiscal 2026 EPS outlook.